Follow this innovation
[ via 
] [?]
Methods to Treat or Prevent Viral Infections, Autoimmune Disease, and Cancer
Temple University
posted on 08/05/2011
The invention provides several new self-tumor antigens, MPD5, PV65 (eIF-2α) and PV13 (protamine 2), which have been found to be immunogenic in patients with polycythemia vera, a myeloproliferative disease. These conventional self-tumor antigens can be used for diagnosis and prognosis, as well as the target for future immunotherapy.
Suggested Uses
• Diagnosis, treatment, monitoring, and/or prevention of viral infections, inflammations, autoimmune disease, polycythemia vera, leukemia, and prostate cancer
• Development of gene therapy vectors in biomedical research and biotechnological engineering, along with a vaccine against cancer
Advantages
• Immune responses to MPD5, PV13 and PV65 self-tumor antigens can be targeted for the purpose of diagnosis, prognosis and immunotherapy for viral infections, inflammation, autoimmune diseases and tumors
• Interferon- α stimulation enhances anti-tumor immune responses via promotion of posttranslational modifications of protein antigens
File Number: 589XY
| Patent Number(s): | PCT/US2007/082605 |
|---|
This innovation currently is not available for online licensing. Please contact Stephen Nappi at Temple University for more information.
request more info
ProfileFind more innovations
